

ZESSLY®▼(INFliximab): PROVIDING COST SAVINGS TO THE NHS VS ORIGINATOR^{1–3}

This is a promotional material produced and funded by Sandoz, intended for UK healthcare professionals only.

Zessly is indicated for the treatment of rheumatoid arthritis (in adults), Crohn's disease (in adults), paediatric Crohn's disease, ulcerative colitis (in adults), paediatric ulcerative colitis, ankylosing spondylitis (in adults), psoriatic arthritis (in adults) and plaque psoriasis (in adults).⁴

Please see the Summary of Product Characteristics for further information.⁴

415664 | July 2024



References: 1. Aladul MI, et al. *BioDrugs* 2017;31(6):533–544; 2. Malik M and Holroyd C. *touchREVIEWs in RMD* 2023;2(1):46–49; 3. Panaccione R. *Crohns Colitis 360* 2021;3:1–7; 4. Zessly® Summary of Product Characteristics 2022.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Sandoz via adverse.event.uk@sandoz.com or online through the pharmacovigilance intake (PVI) tool at <https://pvi1j.solutions.iqvia.com>. If you have a question about the product, please contact Medical Information on 01276 698101 or via email at Sandozgb@EU.propharmagroup.com

Prescribing information is available on the last page or by following the link at the bottom of each page.



MAKE ACCESS HAPPEN AND DELIVER SAVINGS TO THE NHS WITH BIOSIMILARS^{1–4}



- ▶ NHS England **supports** biosimilar to biosimilar **switching** in clinical practice⁵



- ▶ Biosimilars like Zessly help to drive NHS sustainability by **generating savings** that can be **reinvested** into new areas^{1,2}



- ▶ The efficacy and safety profile of **biosimilar switching** to Zessly has been characterised across **real-world studies** involving patients with IBD or IA^{6–8}



- ▶ Zessly is delivered with the **same established infusion protocol** as reference infliximab^{9,10}



- ▶ Sandoz is a **global leader** and **pioneer in biosimilars**, with over two decades of experience¹¹

IA, inflammatory arthritis; IBD, inflammatory bowel disease; NHS, National Health Service.





WITH THE USE OF BIOSIMILARS, THE NHS COULD SAVE UP TO £300 MILLION EACH YEAR¹



► Expand patient access

Biosimilars like Zessly may help to expand patient access to **affordable, efficacious** medicines for autoimmune conditions²⁻⁴



► Improve patient outcomes

Extending the range of treatment options at an **earlier** stage of the therapy pathway, the use of biosimilars has the potential to **enhance outcomes** for more patients^{3,5}



NHS England **supports** biosimilar to biosimilar **switching** in clinical practice⁶

NHS, National Health Service.

CLICK HERE

TO SEE WHAT POTENTIAL SAVINGS
YOU COULD ACHIEVE WITH ZESSLY

+	-
×	=

GO TO CALCULATOR





ZESSLY IS DELIVERED WITH THE SAME ESTABLISHED INFUSION PROTOCOL AS REFERENCE INFILIXIMAB^{1,2}



► Same treatment experience

Your patients can expect the same treatment experience with Zessly as they would with reference infliximab, with an administration process you're familiar with^{1,2}



► Shortened infusions

Shortened infusions are available across adult indications, in carefully selected patients¹

SANDOZ CONTINUES TO INVEST IN THE LIFE CYCLE MANAGEMENT OF ZESSLY TO IMPROVE THE PRODUCT PROFILE^{1,2}

► Longer shelf-life

Zessly can be stored for 4 years before reconstitution vs 3 years with reference infliximab^{1,2}

► Improved out-of-fridge stability

Zessly can be stored at a maximum of 30°C for up to 6 months, compared to reference infliximab, which requires storage at a maximum of 25°C for the same duration before reconstitution^{1,2}

► Smaller pack size

Zessly is now easier to stock and store, with less fridge space needed compared to the previous size³

Offers storage
flexibility^{4,5}



May improve
treatment access
and availability
for patients^{4,5}





SANDOZ IS A GLOBAL LEADER AND PIONEER IN BIOSIMILARS, WITH OVER TWO DECADES OF EXPERIENCE¹



► Pioneering biosimilars

Has led the way in biosimilar development since 2006, launching the world's first biosimilar in the EU, as well as in Australia, Canada, Japan and USA¹



► Working hand in hand with global authorities

Collaborated with European and UK regulatory authorities to develop regulatory pathways and grow understanding of these medicines in patient care²



► Global reach

8 marketed biosimilars across ~100 countries, reaching more patients than any other pharmaceutical company^{1,3}



► Industry-leading portfolio

Has a leading biosimilar portfolio and pipeline in immunology, oncology and endocrinology^{4,5}



► Committed to sustainable development and supply

Made large investments into manufacturing sites to further strengthen its biosimilar development capabilities^{6,7}



► Sandoz has more than 1.3 billion patient days of experience in biosimilars^{*8}

^{*}Rixathon is not included.

EU, European Union; NHS, National Health Service; UK, United Kingdom; USA, United States of America.





ZESSLY'S LONG-TERM SAFETY, EFFICACY AND IMMUNOGENICITY WERE SIMILAR TO REFERENCE INFILIXIMAB^{1,2}

PHASE III REFLECTIONS B537-02 STUDY IN PATIENTS WITH RA



► Similar efficacy

- Therapeutic equivalence was demonstrated between Zessly and reference infliximab based on ACR20 responses at Week 14 (primary endpoint)*³
- Results from treatment periods up to Week 78 support the efficacy of Zessly in patients with moderate-to-severe active RA^{1,2}

**CLINICAL
DATA**

UP TO WEEK 78 >



► Comparable safety and immunogenicity

- Immunogenicity profiles were comparable between Zessly and reference infliximab throughout 30 weeks of treatment, regardless of dose escalation³
- Incidences of anti-drug and neutralising antibodies between Zessly and reference infliximab groups were similar at all time points up to Week 78¹⁻³

**SAFETY
PROFILE**

UP TO WEEK 78 >



- In a Phase I study in healthy volunteers, Zessly showed PK similarity within the prespecified margins, and comparable immunogenicity to reference infliximab⁴

► Real-world evidence

- Real-world data from single or multiple biosimilar switch studies demonstrated that Zessly was well tolerated in patients with IBD or IA⁵⁻⁷

*203 (62.7%) patients in the Zessly arm and 209 patients (64.1%) in the reference infliximab arm achieved ACR20 response at Week 14 demonstrating therapeutic equivalence.³
ACR 20/50/70, A 20/50/70% or greater improvement from baseline in American College of Rheumatology criteria; IA, inflammatory arthritis;
IBD, inflammatory bowel disease; PK, pharmacokinetics; RA, rheumatoid arthritis.





MAKE ACCESS HAPPEN AND DELIVER SAVINGS TO THE NHS WITH BIOSIMILARS^{1–4}



- ▶ NHS England **supports** biosimilar to biosimilar **switching** in clinical practice⁵



- ▶ Biosimilars like Zessly help to drive NHS sustainability by **generating savings** that can be **reinvested** into new areas^{1,2}



- ▶ The efficacy and safety profile of **biosimilar switching** to Zessly has been characterised across **real-world studies** involving patients with IBD or IA^{6–8}



- ▶ Zessly is delivered with the **same established infusion protocol** as reference infliximab^{9,10}



- ▶ Sandoz is a **global leader** and **pioneer in biosimilars**, with over two decades of experience¹¹

IA, inflammatory arthritis; IBD, inflammatory bowel disease; NHS, National Health Service.





ZESSLY BUDGET IMPACT CALCULATOR

All **highlighted cells** are editable and will influence the results of the model

Total	Packs		MGs	
	User	Results	User	Results

